At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 14 enrolled
Drug / intervention
Ferumoxytol-enhanced magnetic resonance imaging +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
In Brief
A Phase 4 clinical trial evaluating Ferumoxytol-enhanced magnetic resonance imaging and Magentic Resonance Imaging for Osteonecrosis. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The goal of the project is to evaluate osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteonecrosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedSep 2016
Primary CompletionOct 2023
TodayJul 2026
First PostedSep 8, 2016
Enrollment StartMay 1, 2015
Primary CompletionOct 31, 2023
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 9.8 years ago
Interventions
Ferumoxytol-enhanced magnetic resonance imagingdrug
Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
Magentic Resonance Imagingdevice
Both arms will receive MRI